

# Real-world hospital treatment patterns in Belgium in early lung cancer between 2018 and 2023: a secondary data analysis [BE-LUNG]

**First published:** 03/02/2026

**Last updated:** 03/02/2026

Study

Finalised

## Administrative details

### EU PAS number

EUPAS1000000397

---

### Study ID

1000000397

---

### DARWIN EU® study

No

---

### Study countries

Belgium

---

### Study description

This multicenter study describes treatment patterns in Belgian patients with stage I-III lung cancer in the period 2018-2023 by leveraging natural language processing and the OMOP common data model.

---

## Study status

Finalised

## Research institutions and networks

### Institutions

#### AZ Maria Middelaes General Hospital

Belgium

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

Hospital/Clinic/Other health care facility

#### AstraZeneca

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

#### Universitair Ziekenhuis Antwerpen (UZA)

Belgium

**First published:** 11/06/2025

**Last updated:** 16/06/2025

**Institution**

Hospital/Clinic/Other health care facility

Laboratory/Research/Testing facility

ENCePP partner

## LynxCare Clinical Informartics

Belgium

**First published:** 20/10/2025

**Last updated:** 20/10/2025

**Institution**

Other

Algemeen Ziekenhuis Groeninge; Universitair  
Ziekenhuis Brussel

## Contact details

### Study institution contact

Katoo Muylle [katoo.muylle@astrazeneca.com](mailto:katoo.muylle@astrazeneca.com)

**Study contact**

[katoo.muylle@astrazeneca.com](mailto:katoo.muylle@astrazeneca.com)

## Primary lead investigator

Katoo Muylle 0000-0003-1117-6709

Primary lead investigator

## ORCID number:

0000-0003-1117-6709

## Study timelines

### Date when funding contract was signed

Actual: 15/05/2024

---

### Study start date

Actual: 06/12/2024

---

### Date of final study report

Planned: 28/02/2025

Actual: 30/04/2025

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

AstraZeneca BeLux

## Regulatory

**Was the study required by a regulatory body?**

No

---

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

Study type

Study type list

**Study topic:**

Disease /health condition

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Disease epidemiology

Drug utilisation

**Data collection methods:**

Secondary use of data

---

**Study design:**

Multicenter study (n = 4) analyzing routinely collected data from pseudonymized electronic health records (EHRs) using natural language

processing (NLP) for unstructured sources. The algorithm mapped variables to a standard terminology, generating OMOP CDM databases, validated per hospital.

**Main study objective:**

- Stage-specific biomarker testing (PD-L1, EGFR, ALK)
- Stage-specific overall survival
- Stage-specific treatment strategies

## Study Design

**Non-interventional study design**

Cohort

## Study drug and medical condition

**Medical condition to be studied**

- Non-small cell lung cancer stage I
- Non-small cell lung cancer stage II
- Non-small cell lung cancer stage III
- Small cell lung cancer limited stage

## Population studied

**Short description of the study population**

Stage I-III non-small cell lung cancer and small cell lung cancer diagnosed between 1 January 2018 and 30 June 2023 with observation time until 31 December 2023

---

**Estimated number of subjects**

1000

## Study design details

### Setting

Belgium, diagnosis between 2018 and 2023

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data source(s)

LynxCare

---

### Data sources (types)

[Electronic healthcare records \(EHR\)](#)

## Use of a Common Data Model (CDM)

### CDM mapping

Yes

## **CDM Mappings**

### **CDM name**

OMOP

---

### **CDM website**

<https://www.ohdsi.org/Data-standardization/>

---

### **CDM version**

5.4

## Data quality specifications

### **Check conformance**

Yes

---

### **Check completeness**

Yes

---

### **Check stability**

Yes

---

### **Check logical consistency**

Yes

## Data characterisation

## **Data characterisation conducted**

Yes

---

## **Data characterisation moment**

after data extraction

after extract-transform-load to a common data model

after creation of study variables